Results 21 to 30 of about 50,442 (246)
Unifying heterogeneous expression data to predict targets for CAR-T cell therapy
OncoImmunology, 2021 Chimeric antigen receptor (CAR) T-cell therapy combines antigen-specific properties of monoclonal antibodies with the lytic capacity of T cells. An effective and safe CAR-T cell therapy strategy relies on identifying an antigen that has high expression ...
Patrick Schreiner +4 more
doaj +1 more source
Folia Histochemica et Cytobiologica, 2010 Numerous experimental data indicate that B-CLL development and progression are influenced by antigenic pressure. It can not be excluded that these antigens may originate from bacteria and viruses.
Barbara Marzec-Kotarska +4 more
doaj +1 more source
Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display
Journal of Translational Medicine, 2023 Background Monoclonal antibody (mAb)-based immunotherapies have achieved promising outcomes in the treatment of immunological and oncological indications. CD19 is considered one of the most qualified antigens in the treatment of B-cell neoplasms.
Mahmoud Ganji +2 more
doaj +1 more source
Scientific Reports, 2023 Tumor-derived extracellular vesicles (EVs) are active contributors in metastasis and immunosuppression in tumor microenvironment. At least some of the EVs carry tumor surface molecules such as tumor-associated antigens (TAAs) and/or checkpoint inhibitors,
V. M. Ukrainskaya +13 more
doaj +1 more source
Distinct and shared B cell responses of tuberculosis patients and their household contacts
PLoS ONE, 2022 This study was aimed at identifying the B cell responses which could distinguish between ‘latent tuberculosis infection (LTBI)’ and active TB disease. Study subjects were smear-positive TB patients (n = 54) and their disease-free household contacts (HHCs,
Komal Singh +5 more
doaj
Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides
Journal of Immunology Research, 2015 We retrospectively analyzed the clinicopathological correlation and prognostic value of cell surface antigens expressed by peripheral blood mononuclear cells in patients with mycosis fungoides (MF). 121 consecutive MF patients were included in this study.
Serkan Yazıcı +9 more
doaj +1 more source
PLoS ONE, 2023 T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn +6 more
doaj +2 more sources
Targeting antigen to CD19 on B cells efficiently activates T cells [PDF]
International Immunology, 2005 CD19 is a B cell-surface molecule that participates as an important regulatory signaling complex for antigen bound at the surface by Ig. Triggering of CD19 through its linkage with CD21 amplifies signals transduced through the Src family kinases and modulates B cell differentiation in response to antigen.
Jun, Yan +4 more
openaire +2 more sources
Chimeric antigen receptor–modified T cells: CD19 and the road beyond [PDF]
Blood, 2018 Abstract The ability to harness a patient’s immune system to target malignant cells is now transforming the treatment of many cancers, including hematologic malignancies. The adoptive transfer of T cells selected for tumor reactivity or engineered with natural or synthetic receptors has emerged as an effective modality, even for patients
Alexander I. Salter +2 more
openaire +2 more sources
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Frontiers in OncologyChimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj +1 more source